Considering Neoadjuvant Chemotherapy Options in Bladder Cancer

Findings from the phase 3 THOR study support the marketing authorization application for erdafitinib as a treatment for those with advanced or metastatic urothelial cancer harboring FGFR3 alterations.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Data from the phase 3 THOR study support the supplemental biologics license application for erdafitinib in previously treated advanced or metastatic urothelial carcinoma with FGFR3 alterations.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Treatment with immune checkpoint inhibitors does not raise any new safety signals among patients with locally advanced or metastatic penile squamous cell carcinoma in an international cohort study.

Amid the recent cisplatin shortages across the United States, a pharmacy expert discusses how the treatment of bladder cancer has been affected, especially in the muscle-invasive subtype.